Pharmaceuticals

Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard

Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cance...

2026-08-12 23:17 3328

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:38 3425

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:10 3397

Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging

VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...

2026-08-11 20:00 2494

Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond

* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...

2026-08-11 19:17 3344

Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility

EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...

2026-08-11 18:00 2612

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...

2026-08-10 19:00 5045

Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"

— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...

2026-08-10 17:36 3419

Alebund's AP301 NDA Accepted for Review by China's NMPA

SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...

2026-08-07 18:40 3652

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...

2026-08-06 18:46 4385

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc

2026-08-06 16:00 1639

Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength

HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...

2026-08-06 13:17 6137

Telix to Host R&D Day in New York City on September 22, 2026

MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional...

2026-08-06 05:00 3092

Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

Advanced Capsule Technology for Improved Digestive Enzyme Delivery SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research showing that its Licaps® DUOCAP® capsule-in-capsule technology can significantly improve the protection and targeted deliv...

2026-08-05 18:39 3501

Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026

SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...

2026-08-05 17:37 2721

Sisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SAR

Harnessing dual-device synergies, multi-energy technologies, and pioneering layered protocols, Sisram cements its strategic leadership across APAC HONG KONG, Aug. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices...

2026-08-05 12:11 2786

NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance

Now commercially available, the medium cut-off dialyzer expands access to enhanced middle molecule removal through existing dialysis infrastructure OSAKA, Japan and BRIDGEWATER, N.J., Aug. 4, 2026 /PRNewswire/ -- NIPRO CORPORATION, through its U.S.-based subsidiary Nipro Medical Corporation, toda...

2026-08-04 22:01 2849

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS  (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deplo...

2026-08-04 18:15 2654

Sisram Medical Powers Up China EBD Growth Engine with Flagship "黑金牛奶光" Launch

Driving Innovation and Proactive Empowerment to Unlock Localized Growth in China HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today un...

2026-08-04 17:37 4957

Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy

At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to improve cancer care. KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRN...

2026-08-04 06:00 15741
1 ... 891011121314 ... 185